Loading
A phase 1/2 trial of Olaparib and Trastuzumab deruxtecan in advanced solid tumours, run by Eisbach Bio GmbH, now recruiting.
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors is a phase 1/2 interventional study registered as NCT06525298 by Eisbach Bio GmbH, with 144 participants planned, started 2024-09-09 and due to reach its primary completion in 2027-09. Interventions recorded: EIS-12656, Olaparib and Trastuzumab deruxtecan.
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.